{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T12:07:18Z","timestamp":1791547638617,"version":"4.3.4"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T00:00:00Z","timestamp":1732492800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","gynecologiconcology-online.net","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.ygyno.2024.11.010","type":"journal-article","created":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T17:43:53Z","timestamp":1733247833000},"page":"102-110","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Analysis of real world FR\u03b1 testing in ovarian, fallopian tube, and primary peritoneal cancers"],"prefix":"10.1016","volume":"192","author":[{"given":"Rebecca A.","family":"Previs","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle C.","family":"Strickland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary","family":"Wallen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Lyon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Biorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Armetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rennie","family":"Quarles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine H.","family":"Watson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kari","family":"Ring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan L.","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Caveney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric A.","family":"Severson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shakti","family":"Ramkissoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ygyno.2024.11.010_bb0005","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2217\/fon-2017-0379","article-title":"A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer","volume":"14","author":"Moore","year":"2018","journal-title":"Future Oncol."},{"key":"10.1016\/j.ygyno.2024.11.010_bb0010","series-title":"Use of Microtubule Targeting Agents in Breast and Ovarian Cancer","author":"Yee","year":"2022"},{"issue":"1","key":"10.1016\/j.ygyno.2024.11.010_bb0015","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J. Clin."},{"issue":"2","key":"10.1016\/j.ygyno.2024.11.010_bb0020","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/s41416-022-02031-x","article-title":"Folate receptor alpha in ovarian cancer tissue and patient serum is associated with disease burden and treatment outcomes","volume":"128","author":"Bax","year":"2023","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ygyno.2024.11.010_bb0025","doi-asserted-by":"crossref","DOI":"10.1177\/1179299X19860815","article-title":"Chemotherapy resistance in advanced ovarian cancer patients","volume":"11","author":"Pokhriyal","year":"2019","journal-title":"Biomark. Cancer"},{"issue":"4","key":"10.1016\/j.ygyno.2024.11.010_bb0030","doi-asserted-by":"crossref","first-page":"280","DOI":"10.3322\/caac.21559","article-title":"Epithelial ovarian cancer: evolution of management in the era of precision medicine","volume":"69","author":"Lheureux","year":"2019","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ygyno.2024.11.010_bb0035","volume":"41","author":"Moore","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.ygyno.2024.11.010_bb0040","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/01.ogx.0000943180.30391.de","article-title":"Efficacy and safety of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer with high folate receptor alpha expression: results from the SORAYA study","volume":"78","author":"Matulonis","year":"2023","journal-title":"Obstet. Gynecol. Surv."},{"issue":"2","key":"10.1016\/j.ygyno.2024.11.010_bb0045","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1080\/14728214.2023.2218643","article-title":"Emerging peptide therapeutics for the treatment of ovarian cancer","volume":"28","author":"Veneziani","year":"2023","journal-title":"Expert Opin. Emerg. Drugs"},{"issue":"1","key":"10.1016\/j.ygyno.2024.11.010_bb0050","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ygyno.2013.03.024","article-title":"Folate receptor alpha (FRA) expression remains unchanged in epithelial ovarian and endometrial cancer after chemotherapy","volume":"130","author":"Despierre","year":"2013","journal-title":"Gynecol. Oncol."},{"issue":"4","key":"10.1016\/j.ygyno.2024.11.010_bb0055","doi-asserted-by":"crossref","first-page":"305","DOI":"10.3322\/caac.21560","article-title":"The current state of molecular testing in the treatment of patients with solid tumors, 2019","volume":"69","author":"El-Deiry","year":"2019","journal-title":"CA Cancer J. Clin."},{"issue":"1\u20132","key":"10.1016\/j.ygyno.2024.11.010_bb0060","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1159\/000479006","article-title":"Ovarian cancer: a heterogeneous disease","volume":"85","author":"Kossa\u00ef","year":"2018","journal-title":"Pathobiology"},{"issue":"8","key":"10.1016\/j.ygyno.2024.11.010_bb0065","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.3390\/cancers11081083","article-title":"The role of intra-tumoral heterogeneity and its clinical relevance in epithelial ovarian cancer recurrence and metastasis","volume":"11","author":"Roberts","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.ygyno.2024.11.010_bb0070","author":"Roche"},{"key":"10.1016\/j.ygyno.2024.11.010_bb0075","author":"FDA"},{"issue":"32","key":"10.1016\/j.ygyno.2024.11.010_bb0080","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.9651","article-title":"Targeting folate receptor alpha for cancer treatment","volume":"7","author":"Cheung","year":"2016","journal-title":"Oncotarget"},{"issue":"16","key":"10.1016\/j.ygyno.2024.11.010_bb0085","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.3739","article-title":"Assessment of folate receptor-\u03b2 expression in human neoplastic tissues","volume":"6","author":"Shen","year":"2015","journal-title":"Oncotarget"},{"issue":"10","key":"10.1016\/j.ygyno.2024.11.010_bb0090","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.1021\/acs.molpharmaceut.7b00464","article-title":"Improved intraoperative detection of ovarian cancer by folate receptor alpha targeted dual-modality imaging","volume":"14","author":"Hekman","year":"2017","journal-title":"Mol. Pharm."},{"issue":"7","key":"10.1016\/j.ygyno.2024.11.010_bb0095","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1158\/1535-7163.MCT-14-1095","article-title":"IMGN853, a folate receptor-\u03b1 (FR\u03b1)\u2013targeting antibody\u2013drug conjugate, exhibits potent targeted antitumor activity against FR\u03b1-expressing tumors","volume":"14","author":"Ab","year":"2015","journal-title":"Mol. Cancer Ther."},{"issue":"2","key":"10.1016\/j.ygyno.2024.11.010_bb0100","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.ygyno.2017.08.015","article-title":"Characterization of folate receptor alpha (FR\u03b1) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: a phase I expansion study of the FR\u03b1-targeting antibody-drug conjugate mirvetuximab soravtansine","volume":"147","author":"Martin","year":"2017","journal-title":"Gynecol. Oncol."},{"issue":"6","key":"10.1016\/j.ygyno.2024.11.010_bb0105","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.annonc.2021.02.017","article-title":"Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I","volume":"32","author":"Moore","year":"2021","journal-title":"Ann. Oncol."},{"issue":"19","key":"10.1016\/j.ygyno.2024.11.010_bb0110","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1158\/1078-0432.CCR-23-0991","article-title":"FDA approval summary: mirvetuximab soravtansine-gynx for FR\u03b1-positive, platinum-resistant ovarian cancer","volume":"29","author":"Dilawari","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2024.11.010_bb0115","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1254532","article-title":"Therapeutic strategies targeting folate receptor \u03b1 for ovarian cancer","volume":"14","author":"Mai","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ygyno.2024.11.010_bb0120","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.ygyno.2023.01.020","article-title":"Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FR\u03b1)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer","volume":"170","author":"Gilbert","year":"2023","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2024.11.010_bb0125","doi-asserted-by":"crossref","first-page":"544","DOI":"10.3390\/medicina59030544","article-title":"Ovarian cancer\u2014insights into platinum resistance and overcoming it","volume":"59","author":"Havasi","year":"2023","journal-title":"Medicina"},{"key":"10.1016\/j.ygyno.2024.11.010_bb0130","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.annonc.2024.04.005","article-title":"Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO precision medicine working group","volume":"135","author":"Mosele","year":"2024","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2024.11.010_bb0135","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s13402-011-0052-6","article-title":"The effect of chemotherapy on expression of folate receptor-alpha in ovarian cancer","volume":"35","author":"Crane","year":"2012","journal-title":"Cell. Oncol. (Dordr)"},{"key":"10.1016\/j.ygyno.2024.11.010_bb0140","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1053\/j.seminoncol.2015.07.013","article-title":"Genetic testing and tissue banking for personalized oncology: analytical and institutional factors","volume":"42","author":"Miles","year":"2015","journal-title":"Semin. Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825824012162?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825824012162?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T01:17:10Z","timestamp":1738718230000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825824012162"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":28,"alternative-id":["S0090825824012162"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2024.11.010","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Analysis of real world FR\u03b1 testing in ovarian, fallopian tube, and primary peritoneal cancers","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2024.11.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}